Pharmacogenetic tests to guide drug treatment in depression: Comparison of the available testing kits and clinical trials

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 86, Issue , 2018, Pages 36-44

  Fabbri, Chiara ^a   Zohar, Joseph ^b,c   Serretti, Alessandro ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b SHEBA MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

Author keywords

Antidepressant; Efficacy; Personalized medicine; Pharmacogenetic test; Pharmacogenetics

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; PSYCHOTROPIC AGENT;

CLINICAL ASSESSMENT; CLINICAL STUDY; DEPRESSION; DRUG LABELING; DRUG TOLERABILITY; EVIDENCE BASED MEDICINE; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; OUTCOME ASSESSMENT; PATIENT CARE; PERSONALIZED MEDICINE; PHARMACOGENETIC TESTING; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; CLINICAL TRIAL (TOPIC); COMPARATIVE STUDY; GENETIC SCREENING; GENETICS; PHARMACOGENETICS; PROCEDURES; STANDARDS;

CLINICAL TRIALS AS TOPIC; DEPRESSION; DRUG LABELING; GENETIC TESTING; HUMANS; PHARMACOGENETICS; PRACTICE GUIDELINES AS TOPIC;

EID: 85047074433     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2018.05.007     Document Type: Review

References (89)

1. AB-Biotics SA, Neuropharmagen [WWW Document]. URL http://international.neurofarmagen.com, 2018. (Accessed 17 January 2018)
2. Admera Health, PGxOne [WWW Document]. URL https://www.admerahealth.com/pgx/, 2018. (Accessed 17 January 2018)
3. Aeon Global Health, Pharmacogenomic test [WWW Document]. URL http://www.aeonglobalhealth.com/services/aeon-clinical-labs/pharmacogenomics/, 2018. (Accessed 17 January 2018)
4. Alpha Genomix, Pharmacogenetic Psychiatry Report [WWW Document]. URL http://www.alphagenomix.com, 2018. (Accessed 17 January 2018)
5. Altar, C.A., Carhart, J., Allen, J.D., Hall-Flavin, D., Winner, J., Dechairo, B., Clinical utility of combinatorial pharmacogenomics-guided antidepressant therapy: evidence from three clinical studies. Mol. Neuropsychiatry 1 (2015), 145–155, 10.1159/000430915.
6. Altar, C.A., Carhart, J.M., Allen, J.D., Hall-Flavin, D.K., Dechairo, B.M., Winner, J.G., Clinical validity: combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes. Pharm. J. 15 (2015), 443–451, 10.1038/tpj.2014.85.
7. Ancillary Medical Solutions, Pharmacogenetic testing [WWW Document]. URL http://www.ancillarymedsolutions.com/pharmacogenetics.php, 2018. (Accessed 17 January 2018)
8. Assurex, GeneSight [WWW Document]. URL https://genesight.com, 2018. (Accessed 17 January 2018)
9. AutoGenomics, INFINITI CYP2C19 Assay [WWW Document]. URL http://www.autogenomics.com/?q=node/218, 2018. (Accessed 17 January 2018)
10. Avera, GeneFolio [WWW Document]. URL https://www.avera.org/innovation-research/genetic-services/genefolio/, 2018. (Accessed 17 January 2018)
11. Bio.logis, Pharmacogenetic panel [WWW Document]. URL https://www.biologis.com, 2018. (Accessed 17 January 2018)
12. BIOGENIQ, BiogeniQ [WWW Document]. URL https://biogeniq.ca/en/our-products/depression-pharma-profile/, 2018. (Accessed 17 January 2018)
13. Bousman, C.A., Hopwood, M., Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry 3 (2016), 585–590, 10.1016/S2215-0366(16)00017-1.
14. Bousman, C.A., Müller, D.J., Ng, C.H., Byron, K., Berk, M., Singh, A.B., Concordance between actual and pharmacogenetic predicted desvenlafaxine dose needed to achieve remission in major depressive disorder: a 10-week open-label study. Pharmacogenet. Genomics 27 (2017), 1–6, 10.1097/FPC.0000000000000253.
15. Boyle, E.A., Li, Y.I., Pritchard, J.K., An expanded view of complex traits: from polygenic to Omnigenic. Cell 169 (2017), 1177–1186, 10.1016/j.cell.2017.05.038.
16. Bradley, P., Shiekh, M., Mehra, V., Vrbicky, K., Layle, S., Olson, M.C., Maciel, A., Cullors, A., Garces, J.A., Lukowiak, A.A., Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J. Psychiatr. Res. 96 (2018), 100–107, 10.1016/j.jpsychires.2017.09.024.
17. Breitenstein, B., Scheuer, S., Pfister, H., Uhr, M., Lucae, S., Holsboer, F., Ising, M., Brückl, T.M., The clinical application of ABCB1 genotyping in antidepressant treatment: a pilot study. CNS Spectr. 19 (2014), 165–175, 10.1017/S1092852913000436.
18. Brennan, F.X., Gardner, K.R., Lombard, J., Perlis, R.H., Fava, M., Harris, H.W., Scott, R., A naturalistic study of the effectiveness of pharmacogenetic testing to guide treatment in psychiatric patients with mood and anxiety disorders. Prim. Care Companion CNS Disord., 17, 2015, 10.4088/PCC.14m01717.
19. Brixner, D., Biltaji, E., Bress, A., Unni, S., Ye, X., Mamiya, T., Ashcraft, K., Biskupiak, J., The effect of pharmacogenetic profiling with a clinical decision support tool on healthcare resource utilization and estimated costs in the elderly exposed to polypharmacy. J. Med. Econ. 19 (2016), 213–228, 10.3111/13696998.2015.1110160.
20. Cacabelos, R., Martinez-Bouza, R., Carril, J.C., Fernandez-Novoa, L., Lombardi, V., Carrera, I., Corzo, L., McKay, A., Genomics and pharmacogenomics of brain disorders. Curr. Pharm. Biotechnol. 13 (2012), 674–725.
21. CGC Genetics, Antidepressants and antipsychotics pharmacogenetics [WWW Document]. URL http://www.cgcgenetics.com/en/by-specialty/929, 2018.
22. Clinical Pharmacogenetics Implementation Consortium, CPIC guidelines [WWW Document]. URL https://cpicpgx.org/guidelines/, 2018. (Accessed 17 January 2018)
23. CNSDose, CNSDose [WWW Document]. URL https://cnsdose.com, 2018. (Accessed 17 January 2018)
24. Dean, L., Codeine therapy and CYP2D6 genotype. Pratt, V., McLeod, H., Dean, L., Malheiro, A., Rubinstein, W., (eds.) Medical Genetics Summaries, 2012, National Center for Biotechnology Information (US), Bethesda (MD).
25. DNA4LIFE, DNA4LIFE [WWW Document]. URL http://www.dna4life.com/wp-content/uploads/2015/09/DNA4Life-Report-Sample.pdf, 2018. (Accessed 17 January 2018)
26. Dreyer, N.A., Velentgas, P., Westrich, K., Dubois, R., The GRACE checklist for rating the quality of observational studies of comparative effectiveness: a tale of hope and caution. J. Manag. Care Spec. Pharm. 20 (2014), 301–308, 10.18553/jmcp.2014.20.3.301.
27. Elliott, L.S., Henderson, J.C., Neradilek, M.B., Moyer, N.A., Ashcraft, K.C., Thirumaran, R.K., Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: a prospective pilot randomized controlled trial. PLoS ONE, 12, 2017, e0170905, 10.1371/journal.pone.0170905.
28. Espadaler, J., Tuson, M., Lopez-Ibor, J.M., Lopez-Ibor, F., Lopez-Ibor, M.I., Pharmacogenetic testing for the guidance of psychiatric treatment: a multicenter retrospective analysis. CNS Spectr. 22 (2017), 315–324, 10.1017/S1092852915000711.
29. Fagerness, J., Fonseca, E., Hess, G.P., Scott, R., Gardner, K.R., Koffler, M., Fava, M., Perlis, R.H., Brennan, F.X., Lombard, J., Pharmacogenetic-guided psychiatric intervention associated with increased adherence and cost savings. Am. J. Manag. Care 20 (2014), e146–e156.
30. Faulkner, E., Annemans, L., Garrison, L., Helfand, M., Holtorf, A.-P., Hornberger, J., Hughes, D., Li, T., Malone, D., Payne, K., Siebert, U., Towse, A., Veenstra, D., Watkins, J., Personalized medicine development and reimbursement working group, Challenges in the development and reimbursement of personalized medicine-payer and manufacturer perspectives and implications for health economics and outcomes research: a report of the ISPOR personalized medicine special interest group. Value Health 15 (2012), 1162–1171, 10.1016/j.jval.2012.05.006.
31. FDA, Table of Pharmacogenomic Biomarkers in Drug Labeling. [WWW Document]. URL https://www.fda.gov/Drugs/ScienceResearch/ucm572698.htm, 2017. (Accessed 27 November 2017)
32. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the global burden of disease study 2015. Lancet 388 (2016), 1545–1602, 10.1016/S0140-6736(16)31678-6.
33. GeneAlign, GeneAlign [WWW Document]. URL https://www.genealign.com/clinicians-pharmacogenetic-testing, 2018. (Accessed 17 January 2018)
34. Genelex, Youscript psychotropic [WWW Document]. URL http://genelex.com/clinical-guidance/psychiatry/, 2018. (Accessed 17 January 2018)
35. GeneTrait Laboratories, GeneTrait Psychotropic Panel [WWW Document]. URL https://www.genetrait.com/testing-options/psychotropic/, 2018. (Accessed 17 January 2018)
36. Geneyouin, Pillcheck [WWW Document]. URL https://www.pillcheck.ca, 2018. (Accessed 17 January 2018)
37. Genomas, HILOmet [WWW Document]. URL http://www.genomas.net/phyziotype-hilomet.php, 2018. (Accessed 17 January 2018)
38. Genomind, Genecept [WWW Document]. URL https://genomind.com/the-genecept-assay/, 2018. (Accessed 17 January 2018)
39. GenXys, TreatGx [WWW Document]. URL https://www.genxys.com/content/, 2018. (Accessed 17 January 2018)
40. Gratten, J., Wray, N.R., Keller, M.C., Visscher, P.M., Large-scale genomics unveils the genetic architecture of psychiatric disorders. Nat. Neurosci. 17 (2014), 782–790, 10.1038/nn.3708.
41. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Jordan, J.J., Nesheim, R.S., Snyder, K.A., Drews, M.S., Eisterhold, L.L., Biernacka, J.M., Mrazek, D.A., Using a pharmacogenomic algorithm to guide the treatment of depression. Transl. Psychiatry, 2, 2012, e172, 10.1038/tp.2012.99.
42. Hall-Flavin, D.K., Winner, J.G., Allen, J.D., Carhart, J.M., Proctor, B., Snyder, K.A., Drews, M.S., Eisterhold, L.L., Geske, J., Mrazek, D.A., Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet. Genomics 23 (2013), 535–548, 10.1097/FPC.0b013e3283649b9a.
43. Healthspek, Healthspek PGT [WWW Document]. URL https://gentechpgt.healthspek.com/#/, 2018. (Accessed 17 January 2018)
44. Higgins, J.P.T., Altman, D.G., Gøtzsche, P.C., Jüni, P., Moher, D., Oxman, A.D., Savovic, J., Schulz, K.F., Weeks, L., Sterne, J.A.C., Cochrane Bias Methods Group, Cochrane Statistical Methods Group, The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343, 2011, d5928.
45. Hodgson, K., Tansey, K., Dernovsek, M.Z., Hauser, J., Henigsberg, N., Maier, W., Mors, O., Placentino, A., Rietschel, M., Souery, D., Smith, R., Craig, I.W., Farmer, A.E., Aitchison, K.J., Belsey, S., Belsy, S., Davis, O.S.P., Uher, R., McGuffin, P., Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J. Psychopharmacol. Oxf. Engl. 28 (2014), 133–141, 10.1177/0269881113512041.
46. Hodgson, K., Tansey, K.E., Uher, R., Dernovšek, M.Z., Mors, O., Hauser, J., Souery, D., Maier, W., Henigsberg, N., Rietschel, M., Placentino, A., Craig, I.W., Aitchison, K.J., Farmer, A.E., Dobson, R.J.B., McGuffin, P., Exploring the role of drug-metabolising enzymes in antidepressant side effects. Psychopharmacology 232 (2015), 2609–2617, 10.1007/s00213-015-3898-x.
47. Hornberger, J., Li, Q., Quinn, B., Cost-effectiveness of combinatorial pharmacogenomic testing for treatment-resistant major depressive disorder patients. Am. J. Manag. Care 21 (2015), e357–e365.
48. Jain, K.K., Applications of AmpliChip CYP450. Mol. Diagn. 9 (2005), 119–127.
49. Katsanis, S.H., Minear, M.A., Vorderstrasse, A., Yang, N., Reeves, J.W., Rakhra-Burris, T., Cook-Deegan, R., Ginsburg, G.S., Simmons, L.A., Perspectives on genetic and genomic technologies in an academic medical center: the duke experience. J. Pers. Med. 5 (2015), 67–82, 10.3390/jpm5020067.
50. Lab Tests Online, Pharmacogenomic tests [WWW Document]. URL https://labtestsonline.org/tests/pharmacogenetic-tests, 2018. (Accessed 17 January 2018)
51. LabCorp, Pharmacogenetic testing [WWW Document]. URL https://www.labcorp.com/help/patient-test-info/pharmacogenetic-tests, 2018. (Accessed 17 January 2018)
52. Liberati, A., Altman, D.G., Tetzlaff, J., Mulrow, C., Gøtzsche, P.C., Ioannidis, J.P.A., Clarke, M., Devereaux, P.J., Kleijnen, J., Moher, D., The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med., 6, 2009, e1000100, 10.1371/journal.pmed.1000100.
53. Mayo Clinic, Drug-gene testing [WWW Document]. URL http://mayoresearch.mayo.edu/center-for-individualized-medicine/drug-gene-testing.asp, 2018. (Accessed 17 January 2018)
54. MD labs, Rxight [WWW Document]. URL https://rxight.com, 2018. (Accessed 17 January 2018)
55. Medigenetics, Pharmacogenetic DNA Testing [WWW Document]. URL https://www.medigenetics.eu, 2018. (Accessed 5 April 2018)
56. Millennium Health, Millennium PGT [WWW Document]. URL http://www.millenniumhealth.com/services/pgt-testing/, 2018. (Accessed 17 January 2018)
57. Mizutani, T., PM frequencies of major CYPs in Asians and Caucasians. Drug Metab. Rev. 35 (2003), 99–106, 10.1081/DMR-120023681.
58. Mullins, N., Lewis, C.M., Genetics of depression: progress at last. Curr. Psychiatry Rep., 19(43), 2017, 10.1007/s11920-017-0803-9.
59. MyDNA, MyDNA [WWW Document]. URL https://www.mydna.life, 2018. (Accessed 17 January 2018)
60. Niitsu, T., Fabbri, C., Bentini, F., Serretti, A., Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 45 (2013), 183–194, 10.1016/j.pnpbp.2013.05.011.
61. OneOme, RightMed [WWW Document]. URL https://oneome.com/rightmed-comprehensive, 2018. (Accessed 17 January 2018)
62. Papastergiou, J., Tolios, P., Li, W., Li, J., The innovative Canadian Pharmacogenomic screening initiative in community pharmacy (ICANPIC) study. J. Am. Pharm. Assoc. 57 (2017), 624–629, 10.1016/j.japh.2017.05.006.
63. Pathway genomics, Mental Health DNA Insight [WWW Document]. URL https://www.pathway.com/mental-health-dna-insight/, 2018. (Accessed 17 January 2018)
64. Pérez, V., Salavert, A., Espadaler, J., Tuson, M., Saiz-Ruiz, J., Sáez-Navarro, C., Bobes, J., Baca-García, E., Vieta, E., Olivares, J.M., Rodriguez-Jimenez, R., Villagrán, J.M., Gascón, J., Cañete-Crespillo, J., Solé, M., Saiz, P.A., Ibáñez, Á., de Diego-Adeliño, J. AB-GEN Collaborative Group, Menchón, J.M., Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry, 17, 2017, 250, 10.1186/s12888-017-1412-1.
65. Perlis, R.H., Pharmacogenomic testing and personalized treatment of depression. Clin. Chem. 60 (2014), 53–59, 10.1373/clinchem.2013.204446.
66. Peterson, J.F., Field, J.R., Shi, Y., Schildcrout, J.S., Denny, J.C., McGregor, T.L., Van Driest, S.L., Pulley, J.M., Lubin, I.M., Laposata, M., Roden, D.M., Clayton, E.W., Attitudes of clinicians following large-scale pharmacogenomics implementation. Pharm. J. 16 (2016), 393–398, 10.1038/tpj.2015.57.
67. Peterson, K., Dieperink, E., Anderson, J., Boundy, E., Ferguson, L., Helfand, M., Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder. Psychopharmacology 234 (2017), 1649–1661, 10.1007/s00213-017-4622-9.
68. PharmGKB, Dosing Guidelines [WWW Document]. PharmGKB. URL https://www.pharmgkb.org/guidelines, 2018. (Accessed 23 December 2017)
69. PharmGKB, Drug Labels | PharmGKB [WWW Document]. URL https://www.pharmgkb.org/labels, 2018. (Accessed 23 December 2017)
70. Quest Diagnostics, Antidepressant panel [WWW Document]. URL http://www.questdiagnostics.com/testcenter/BUOrderInfo.action?tc=30708&labCode=DLO, 2018. (Accessed 17 January 2018)
71. Rahman, T., Ash, D.M., Lauriello, J., Rawlani, R., Misleading guidance from Pharmacogenomic testing. Am. J. Psychiatry 174 (2017), 922–924, 10.1176/appi.ajp.2017.16121353.
72. RenaissanceRX, RenaissanceRX [WWW Document]. URL http://www.renrx.com/provider/laboratory-services/, 2018.
73. Rosenblat, J.D., Lee, Y., McIntyre, R.S., Does Pharmacogenomic testing improve clinical outcomes for major depressive disorder? A systematic review of clinical trials and cost-effectiveness studies. J. Clin. Psychiatry 78 (2017), 720–729, 10.4088/JCP.15r10583.
74. Ruaño, G., Szarek, B.L., Villagra, D., Gorowski, K., Kocherla, M., Seip, R.L., Goethe, J.W., Schwartz, H.I., Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder. Biomark. Med 7 (2013), 429–439, 10.2217/bmm.13.16.
75. Singh, A.B., Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene Pharmacogenetic report. Clin. Psychopharmacol. Neurosci. 13 (2015), 150–156, 10.9758/cpn.2015.13.2.150.
76. Sonic Genetics, Pharmacogenetic Screen [WWW Document]. URL https://www.sonicgenetics.com.au/tests/pharmacogenetic-screen/, 2018. (Accessed 17 January 2018)
77. Souery, D., Serretti, A., Calati, R., Oswald, P., Massat, I., Konstantinidis, A., Linotte, S., Bollen, J., Demyttenaere, K., Kasper, S., Lecrubier, Y., Montgomery, S., Zohar, J., Mendlewicz, J., Switching antidepressant class does not improve response or remission in treatment-resistant depression. J. Clin. Psychopharmacol. 31 (2011), 512–516, 10.1097/JCP.0b013e3182228619.
78. Stamm, T.J., Rampp, C., Wiethoff, K., Stingl, J., Mössner, R., O Malley, G., Ricken, R., Seemüller, F., Keck, M., Fisher, R., Gaebel, W., Maier, W., Möller, H.-J., Bauer, M., Adli, M., The FKBP5 polymorphism rs1360780 influences the effect of an algorithm-based antidepressant treatment and is associated with remission in patients with major depression. J. Psychopharmacol. Oxf. Engl. 30 (2016), 40–47, 10.1177/0269881115620459.
79. Stanek, E.J., Sanders, C.L., Taber, K.A.J., Khalid, M., Patel, A., Verbrugge, R.R., Agatep, B.C., Aubert, R.E., Epstein, R.S., Frueh, F.W., Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin. Pharmacol. Ther. 91 (2012), 450–458, 10.1038/clpt.2011.306.
80. Sterne, J.A., Hernán, M.A., Reeves, B.C., Savović, J., Berkman, Viswanathan, M., Henry, D., Altman, D.G., Ansari, M.T., Boutron, I., Carpenter, J.R., Chan, A.-W., Churchill, R., Deeks, J.J., Hróbjartsson, A., Kirkham, J., Jüni, P., Loke, Y.K., Pigott, T.D., Ramsay, C.R., Regidor, D., Rothstein, H.R., Sandhu, L., Santaguida, P.L., Schünemann, H.J., Shea, B., Shrier, I., Tugwell, P., Turner, L., Valentine, J.C., Waddington, H., Waters, E., Wells, G.A., Whiting, P.F., Higgins, J.P., ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ, 355, 2016, i4919.
81. SureGene and PGxl, STA2R [WWW Document]. URL https://www.suregenetest.com, 2018. (Accessed 17 January 2018)
82. Tansey, K.E., Guipponi, M., Hu, X., Domenici, E., Lewis, G., Malafosse, A., Wendland, J.R., Lewis, C.M., McGuffin, P., Uher, R., Contribution of common genetic variants to antidepressant response. Biol. Psychiatry 73 (2013), 679–682, 10.1016/j.biopsych.2012.10.030.
83. Thermo Fisher Scientific, PharmacoScan [WWW Document]. URL https://www.thermofisher.com/us/en/home/products-and-services/promotions/life- science/pharmacoscan-solution.html, 2018. (Accessed 17 January 2018)
84. Trivedi, M.H., Rush, A.J., Wisniewski, S.R., Nierenberg, A.A., Warden, D., Ritz, L., Norquist, G., Howland, R.H., Lebowitz, B., McGrath, P.J. et al., Evaluation of outcomes with citalopram for depression using measurement-based care in STAR* D: implications for clinical practice. Am. J. Psychiatry 163 (2006), 28–40.
85. Vantari Genetics, Drug metabolism [WWW Document]. URL http://www.vantarigenetics.com/drug-metabolism, 2018. (Accessed 17 January 2018)
86. Verbeurgt, P., Mamiya, T., Oesterheld, J., How common are drug and gene interactions? Prevalence in a sample of 1143 patients with CYP2C9, CYP2C19 and CYP2D6 genotyping. Pharmacogenomics 15 (2014), 655–665, 10.2217/pgs.14.6.
87. Winner, J., Allen, J.D., Altar, C.A., Spahic-Mihajlovic, A., Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl. Psychiatry, 3, 2013, e242, 10.1038/tp.2013.2.
88. Winner, J.G., Carhart, J.M., Altar, C.A., Allen, J.D., Dechairo, B.M., A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov. Med. 16 (2013), 219–227.
89. Winner, J.G., Carhart, J.M., Altar, C.A., Goldfarb, S., Allen, J.D., Lavezzari, G., Parsons, K.K., Marshak, A.G., Garavaglia, S., Dechairo, B.M., Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation. Curr. Med. Res. Opin. 31 (2015), 1633–1643, 10.1185/03007995.2015.1063483.